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ABSTRACT: 
 
Background: In pulmonary arterial hypertension (PAH), pathological changes in pulmonary 
arterioles progressively raise pulmonary artery pressure and increase pulmonary vascular 
resistance, leading to right heart failure and high mortality rates. Recently, the first potassium 
channelopathy in PAH, due to mutations in KCNK3, was identified as a genetic cause and 
pharmacological target. 
Methods: Exome sequencing was performed to identify novel genes in a cohort of 99 pediatric 
and 134 adult onset group I pulmonary arterial hypertension patients. Novel rare variants in the 
gene identified were independently identified in a cohort of 680 adult onset patients. Variants 
were expressed in COS cells and function assessed by patch-clamp and rubidium flux analysis. 
Results: We identified a de novo novel heterozygous predicted deleterious missense variant 
c.G2873A (p.R958H) in ABCC8 (ATP-binding cassette, subfamily C, member 8) in a child with 
idiopathic PAH. We then evaluated all individuals in the original and a second cohort for rare or 
novel variants in ABCC8 and identified 11 additional heterozygous predicted damaging ABCC8 
variants. ABCC8 encodes sulfonylurea receptor 1 (SUR1), a regulatory subunit of the ATP-
sensitive potassium channel (KATP). We observed loss of KATP function for all ABCC8 variants 
evaluated, and pharmacological rescue of all channel currents in vitro by the SUR1 activator, 
diazoxide.  
Conclusions: Novel and rare miss nse variants in ABCC8 are associated with pulmonary arterial 
hypertension. Identified ABCC8 mutations decreased KATP channel function, which was 
pharmacologically recovered. 
 
 
 
 
Key words: pulmonary hypertension; genetics, human; electrophysiology; ion channel; 
pharmacology; ABCC8; SUR1 
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INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a rare and often fatal disease characterized by 
distinctive changes in pulmonary arterioles that lead to elevated pulmonary artery pressure and 
right sided heart failure. Novel treatment options have decreased mortality, but PAH remains a 
frequently fatal illness. The heterogeneity in disease etiology and nonspecific patient 
presentation often delays diagnosis, contributing to poor outcomes.  
Genetics are recognized to play an important role in the pathogenesis of PAH in patients 
with and without a family history of disease. Most genetic studies of the disease have been 
performed in patients with adult-onset disease. Germline mutations in bone morphogenetic 
protein receptor type 2 (BMPR2), a member of the transforming growth factor ȕ 7*)ȕ 
superfamily of receptors, have been identified as the major genetic cause, including in 70% of 
inherited and 10±40% of idiopathic cases.1, 2  Mutations in other 7*)ȕ family members 
comprise additional rare genetic causes. The prevalence of the disease in children is estimated at 
2.2 cases per million, an order of magnitude lower than the estimated prevalence of 15-50 cases 
per million in adults,3 and there are few genetic studies of individuals with childhood-onset PAH.  
We previously used exome sequencing to identify mutations in the KCNK3 potassium 
channel as a genetic cause of idiopathic and familial PAH.4 Furthermore, we proposed KCNK3 
as a novel pharmacological target in PAH, as potassium channel currents of select mutant and 
wildtype KCNK3 channels were pharmacologically remedied by ONO-RS-082, an experimental 
compound.4, 5 In the current study, we report a novel association of ABCC8/ SUR1 loss of 
function mutations in both pediatric and adult onset PAH. ABCC8 encodes sulfonylurea receptor 
1 (SUR1), a regulatory subunit of the ATP-sensitive potassium channel (KATP). We have 
functionally assessed mutant KATP channels, and characterized their pharmacological activation. 
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METHODS 
The sequencing data and methods will be made available to other researchers for purposes of 
reproducing the results or replicating the procedures.  The study was approved by the 
institutional review board at Columbia University Medical Center. Detailed methods are 
available as supplemental data. 
 
RESULTS 
Inherited and de novo variants in ABCC8 
By exome sequencing, we identified a de novo missense variant c.G2873A (p.R958H) in ATP-
binding cassette, subfamily C, member 8 (ABCC8) (NM_001287174), which was predicted to be 
deleterious, in a patient diagnosed with idiopathic PAH at the age of 10 (Table 1). We then 
examined all CU-PAH patients for rare or novel variants in ABCC8 and identified seven 
additional rare damaging missense variants, predicted by multiple algorithms to be deleterious in 
seven unrelated patients with idiopathic, familial, or congenital heart disease associated 
pulmonary arterial hypertension (Table 1). In one familial case, the p.A240T variant was 
transmitted from an affected father and also observed in the affected sibling. To replicate the 
findings in the CU-PAH cohort, we evaluated the UK-PAH cohort and identified three additional 
rare or novel missense and one splice variant in ABCC8 in three patients with idiopathic and one 
patient with congenital heart disease associated PAH (Table 1). Five variants ± c.A214G 
(p.N72D), c.G558T (p.E186D), c.G718A (p.A240T), c.G2371C (p.E791Q), and c.T2694+2G -- 
were novel; four rare variants ± c.G331A (p.G111R), c.C403G (p.L135V), c.G2437A 
(p.D813N), and c.G4414A (p.D1472N) -- have been reported in patients with congenital 
hyperinsulinism; and two variants ± c.C686T (p.T229I) and c.G3941A (p.R1314H) ± have been 
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reported in patients with transient or permanent neonatal diabetes mellitus.6-12 Alignment of the 
ABCC8 sequence revealed that all missense variants occur at amino acid residues conserved 
across species and in critical domains (Figure 1A and 1B). 
 All individuals were heterozygous for these rare ABCC8 variants. The L135V, D813N, 
and R1314H variants were inherited from an unaffected father and represented PAH risk variants 
in childhood-onset PAH, while E791Q and D1472N were inherited from an unaffected mother 
and represented PAH risk variants in childhood-onset PAH. The ABCC8 p.R1314H carrier also 
had a TBX4 c.1106delC: p.S369fs mutation. None of the other ABCC8 carriers had mutations in 
any known PAH genes. Other predicted deleterious variants throughout the genome carried by 
the ABCC8 discovery cohort are listed in Supplementary Table S1. Seven of the probands were 
female and five were male. None of the probands had any evidence of hyperinsulinism or 
transient/permanent neonatal diabetes mellitus although one adult patient had type 2 diabetes. 
Six of the patients were children at the time of diagnosis. Three patients responded and four 
patients did not respond to acute vasodilator testing using inhaled nitric oxide during cardiac 
catheterization. Two patient had evidence of a cardiac arrhythmia (Table 1). 
To estimate the genetic effect size of ABCC8 variants, we selected 33,369 European adult 
subjects from Exome Aggregation Consortium (ExAC) and 49,630 European ancestry subjects 
from the Regeneron-Geisinger DiscovEHR study independently as controls,13 and tested for an 
H[FHVVRIUDUHPLQRUDOOHOHIUHTXHQF\SUHGLFWHGGHOHWHULRXVPLVVHQVHYDUiants in cases 
compared to controls. There were six rare predicted deleterious alleles in 150 PAH cases of 
European ancestry in the CU-PAH cohort, while 158 unique deleterious variants were observed a 
total of 295 times in 33,369 controls with exome sequencing in the ExAC dataset and 165 rare 
unique deleterious variants were observed 712 times in the DiscovEHR study. With binomial 
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tests, we observed significant excess of rare predicted deleterious missense variants in ABCC8 in 
CU-PAH cases when comparing to ExAC controls (P-value = 0.0023, Enrichment rate = 4.5) and 
to DiscovEHR controls (P-value = 0.022, Enrichment rate = 2.8). We tested the association of 
predicted benign ABCC8 variants and identified two rare synonymous alleles in cases, 223 
unique predicted benign missense variants or synonymous variants observed a total of 512 times 
in controls, and found no significant difference between the CU-PAH group and ExAC (P-value 
= 1; relative risk = 0.87). 
ABCC8 expression in human lung 
ABCC8 encodes the sulfonylurea receptor 1 (SUR1) protein, a regulatory subunit of the KATP 
channel, which associates with the pore-forming Kir6.2 subunit.14 SUR1 controls cell excitability 
by regulating trafficking and expression of the KATP channel, and confers sensitivity of KATP 
channels to magnesium-nucleotides and pharmacological modulators. SUR1-dependent KATP 
channels are prominent in neuronal and pancreatic tissues, but present in many other tissues, 
including cardiac atria.14-16 We demonstrate that ABCC8 is expressed in lungs of patients with 
PAH and in healthy individuals (Supplementary Figure S1), providing a potential target for 
influencing and modulating PAH. We replicated our finding of ABCC8 gene expression in a 
second set of lung samples from heritable PAH patients with known BMPR2 mutations (HPAH) 
and healthy controls. We observed a significant increase in ABCC8 expression in lungs of 
BMPR2-associated HPAH patient samples (Supplementary Figure S2).  
To determine the cell types expressing SUR1 protein in lungs of idiopathic PAH (IPAH) 
patients, confocal microscopic analyses and triple labeling with ABCC8, CD68 and SM22 
antibodies were used in paraffin-embedded lungs from six IPAH patient lung samples. Strong 
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staining for SUR1 was found in a population of alveolar macrophages, and moderate staining for 
SUR1 was observed in proximal pulmonary arteries (Supplementary Figure S3). 
Functional characterization of ABCC8 mutations 
We examined the consequence of eight of the twelve identified ABCC8 variants putatively 
associated with PAH on SUR1 function using two complementary measures of KATP activity: (1) 
patch-clamp electrophysiology provided a direct measurement of whole cell KATP conductance in 
individual cells across different membrane potentials; and (2) rubidium (86Rb+) flux assays 
provided quantification of channel activity using 86Rb+ efflux as a measure of macroscopic KATP 
conductance from a population of intact cells.  By co-expressing Kir6.2 with SUR1 in COS cells, 
functional KATP channels were formed in each assay. All SUR1 variants tested demonstrated loss 
of function in at least one functional assay. 
First, we used patch-clamp experiments to directly measure SUR1-dependent KATP 
channel activity by applying a voltage ramp in whole-cell conditions (Figure 2A), using an 
established assay.17 We maximally activated KATP channel currents with diazoxide (100µM), a 
selective SUR1 activator. Once steady-state diazoxide current activation was achieved, 
glibenclamide (10µM) ± which inhibits KATP channels by binding to the SUR subunit ± was co-
applied. The glibenclamide-sensitive current was taken as the SUR1-dependent KATP current.17  
A series of control xperiments for assay validation are shown in Supplementary Figures S4 and 
S5. 
Robust SUR1-dependent KATP currents were measured in cells expressing Kir6.2 and 
wildtype SUR1 (Figure 2B). By contrast, currents were much smaller in cells expressing A240T 
SUR1, one of the novel SUR1 variants identified. Similarly small currents were observed in cells 
expressing D813N or D1472N SUR1, previously reported mutations in congenital 
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hyperinsulinism (Figure 2B). Further analysis demonstrated significantly reduced SUR1-
dependent currents in six of eight SUR1 mutants functionally evaluated (E186D, A240T, E791Q, 
D813N, R1314H, and D1472N), and non-significant reductions in L135V and R958H (Figure 
2C). 
Next, 86Rb+ efflux rate was recorded as a measure of KATP channel activity in cells 
expressing wildtype or mutant SUR1 along with Kir6.2 (Figure 3), in basal metabolic conditions 
and in metabolic inhibition. Compared to wildtype SUR1, basal conditions yielded marked 
decreases in efflux rate for the A240T, D813N, and D1472N variants, and smaller decreases for 
L135V, E791Q, R958H, and R1314H [Figure 3A and 3B; Supplementary Table S1]. In 
metabolic inhibition (extracellular solution supplemented with 2-deoxy-D-glucose and 
oligomycin to impair ATP synthesis and relieve KATP channels from inhibition by intracellular 
nucleotides), the flux rates for the L135V, A240T, D813N, R958H and D1472N mutants were 
markedly lower than wildtype (Figure 3C and 3D; Supplementary Table S2). The E791Q and 
R1314H mutant fluxes were slightly reduced, while no decrease in flux under basal or metabolic 
inhibition conditions was observed for E186D. 
Thus, when combining results from the whole-cell patch clamp and rubidium flux 
functional assays, there was a significant decrease in basal and/or maximal channel activity for 
all SUR1 mutants associated with PAH that were functionally tested. SUR1 and KATP loss of 
function could result from various mechanisms, but any channel activity present might be 
augmented by selective potassium channel opening drugs, such as diazoxide. Consistent with this 
suggestion, all mutants tested were pharmacologically activated by diazoxide (100µM) in 
rubidium efflux (Figure 4A and 4B; Supplementary Table S3), and whole-cell patch clamp 
(Figure 4C and 4D; Supplementary Figure S4-F).  
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DISCUSSION 
Using exome sequencing, we identified de novo and inherited heterozygous mutations in a novel 
candidate gene, ABCC8, potentially associated with idiopathic, familial, and congenital heart 
disease associated PAH, in eight independent families, with six of the probands diagnosed as 
children in the CU-PAH study. We identified an additional four rare or novel predicted 
damaging missense and splice variants in ABCC8 in a second cohort (UK-PAH) of adult group I 
PAH patients with idiopathic, familial, congenital heart disease-associated or appetite drug-
associated disease. The mutations are incompletely penetrant similar to most other genes for 
PAH, and penetrance may depend on additional genetic or environmental modifiers. Functional 
analyses demonstrated reduced ATP-sensitive potassium (KATP) channel activity in all SUR1 
mutants tested and pharmacological rescue of KATP activity in vitro by diazoxide. 
ABCC8 encodes the sulfonylurea receptor 1 (SUR1) protein, a KATP channel subunit. The 
eleven identified missense ABCC8 variants are all rare, located at residues highly conserved 
across species, and reside in intracellular and transmembrane domains of SUR1, including 
nucleotide binding fold regions (Figure 1). ABCC8 is highly expressed in the human brain and 
endocrine pancreas, and moderately expressed in human lungs18 (Supplementary Figures S1 and 
S2). SUR1 expression has been observed in intact rat pulmonary arteries,19 while KATP channel 
activity was shown to be upregulated by elevated shear stress in pulmonary vascular endothelial 
cells.20 More recently, SUR1 upregulation by hypoxia was reported in cerebral microvascular 
endothelial cells.21, 22 As we have observed upregulation of ABCC8 in BMPR2-associated 
heritable PAH patient samples (Supplementary Figure S2), as well as SUR1 protein in both 
alveolar macrophages and proximal pulmonary arteries within the lung (Supplementary Figure 
S3), further studies may elucidate 685¶V primary physiologic role in the pulmonary 
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10 
vasculature, and how exactly its dysfunction and subsequent reduction in KATP currents 
contribute to PAH in some patients.  
KCNK3, established as the first potassium channelopathy in PAH,4, 5, 23 is also regulated 
by hypoxia in pulmonary artery smooth muscle cells, and may contribute to hypoxic pulmonary 
vasoconstriction.24 In the lung, SUR1-dependent KATP channel loss of function alongside 
KCNK3 channel loss of function represent possible pathogenic mechanisms in PAH, and 
pharmacologic recovery of channel function a therapeutic avenue.4, 5, 23 Moreover, heteromeric 
channel assembly of SUR1 and KCNK3 with related channel subunits is well documented for 
both KATP and KCNK3 in various organs.14, 25, 26 This complementary and redundant potassium 
channel activity could contribute to the lung-specific phenotype observed clinically in patients 
with heterozygous ABCC8 or KCNK3 mutation.5 
Despite loss of ABCC8 function underlying many cases of congenital hyperinsulinism, 
the patients in our study have no evidence of hyperinsulinemic hypoglycemia or 
transient/permanent neonatal diabetes mellitus. This raises the question: why do SUR1-
dependent PAH patients not have hyperinsulinism, and vice versa, why do hyperinsulinism 
patients not have evidence of PAH? Ultimately, a combination of genetic, developmental, and 
environmental factors may determine which patients with ABCC8 mutations develop PAH.  
The mechanism of SUR1 loss of function likely varies based on mutation location with 
the channel subunit. For instance, G111R and D1472N have been previously shown to decrease 
SUR1 trafficking to the plasma membrane,7, 12, 27 while nucleotide binding fold mutations, 
D813N and R958H, may impair magnesium-nucleotide activation. SUR1 mutation severity 
impacts viability for pharmacological rescue, as previously demonstrated for KCNK3 mutant 
channels associated with PAH,4, 5 and for SUR1 mutants associated with congenital 
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11 
hyperinsulinism.28 Alongside pharmacological activation of SUR1-containing KATP channels, 
ascertaining the mechanism of loss of function of all SUR1 variants in our study has important 
implications for disease pathogenesis and the therapeutic potential of KATP activation in PAH. 
Understanding mechanism of dysfunction may be accomplished by screening for SUR1 defects 
in trafficking, gene expression, regulation by nucleotides, and post-translational modifications. 
As mainstay treatment in congenital hyperinsulinism, diazoxide administr tion 
overcomes disease-causing ABCC8 loss-of-function mutations. We observed variable functional 
recovery in vitro by diazoxide of each SUR1 mutant tested in our study of PAH patients with 
ABCC8 mutations. Diazoxide is a SUR1 activator clinically employed as an anti-hypertensive 
and anti-hyperinsulinism agent. Case reports from many years ago described the successful use 
of diazoxide to reverse pulmonary hypertension; 29, 30 however, hypoglycemic infants treated 
with diazoxide have developed pulmonary hypertension.31 This may be secondary to inadequate 
diuresis with diazoxide treatment, leading to volume overload following systemic blood volume 
expansion. Until diazoxide is proven to be safe, we do not recommend diazoxide as a treatment 
for pulmonary hypertension. While SUR1-dependent KATP activation is an intriguing potential 
basis for pulmonary hypertension therapy,32 ultimately, KATP channel activators with less 
pulmonary toxicity may prove useful for pulmonary hypertension treatment.33 
In conclusion, we have identified mutations in the ABCC8 gene as a potential second 
potassium channelopathy in PAH, and as a possible therapeutic target. 
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7DEOH3DWKRJHQLFLW\3UHGLFWLRQVDQG&OLQLFDO&KDUDFWHULVWLFVRI3DWLHQWVZLWK3XOPRQDU\$UWHULDO+\SHUWHQVLRQZLWK$%&&
0XWDWLRQV([$&IUHTXHQF\OLVWVWKHDOOHOHIUHTXHQF\IRUDOORI([$&IROORZHGE\WKHDOOHOHIUHTXHQF\LQWKHSDWLHQW¶VHWKQLFJURXS 
Nucleotide and  
AA variant 
c.A214G: 
p.N72D 
c.G331A: 
p.G111R 
c.C403G: 
p.L135V 
c.G558T: 
p.E186D 
c.C686T: 
p.T229I 
c.G718A: 
p.A240T 
c.G2371C: 
p.E791Q 
c.G2437A: 
p.D813N 
c.G2873A: 
p.R958H 
c.G3941A: 
p.R1314H 
c.G4414A:p
.D1472N 
c.T2694+2G:
p.NA 
ExAC_Freq 0 0.00002/ 0.00001 
0.00003/ 
0.00006 0 
0.000008/ 
0.00001 0 0 
0.0001/ 
0.0012 
0.00002/ 
0.00001 
0.00002/ 
0.00001 0 0 
Ethnicity Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Hispanic Asian  Caucasian Caucasian Caucasian Caucasian 
MetaSVM_pred D D D D D D D D D D D N/A 
CADD_phred 22.8 28.4 20.5 19.46 29.4 35 32 35 27.9 23 22.4 25.1 
Cohort UK UK CU CU UK CU CU CU CU CU CU UK 
PAH type CHD 
associated Idiopathic Idiopathic Idiopathic Idiopathic 
Familial;  
Sister 
and father 
with PAH  
Familial;  
two deceased 
affected  
siblings not 
tested 
Idiopathic Idiopathic CHD- 
associated Idiopathic Idiopathic 
Inheritance/ 
segregation Unknown Unknown Paternal Unknown Unknown 
Paternal; 
father and 
affected 
sister carry 
p.A240T 
Maternal; 
affected 
siblings 
unavailable 
for analysis 
Paternal De novo Paternal Maternal Unknown 
Gender F M M M F F F M F M F F 
Age of  
diagnosis 35 64 5 79 34 Unknown 14 12 10 <1 9 60 
RAP M (mmHg) N/A 11 9 N/A 9 N/A N/A 25 6 8 7 7 
PAP M (mmHg) N/A 44 55 N/A 45 N/A N/A 54 56 54 37 36 
AOP M (mmHg) N/A Unknown 78 N/A Unknown N/A N/A 48 88 57 67 Unknown 
PVRi (U*m2) N/A 19 25 N/A 13 N/A N/A 29 16 13.6 17 19 
Art Sat % N/A 97 91 N/A 98 N/A N/A 93 91 97 96 97 
PCWPm (mmHg) N/A 15 8 N/A 10 N/A N/A N/A 8 8 N/A 6 
CI (L/min/m2) N/A 1.5 2.8 N/A 2.7 N/A N/A N/A 2.8 3.5 2 1.6 
Response to acute 
vasodilator test N/A Unknown Yes Unknown No Unknown Unknown No Yes No Yes No 
Other genetic 
variants in  PAH 
genes 
None None None None None None None None None 
TBX4  
c.1106delC:
p.S369fs 
None None 
Cardiac 
arrhythmias; 
other conditions 
Large 
atrial 
septal 
defect 
Type 2 
Diabetes  
Mellitus 
Bigeminy,  
1st degree  
heart 
block 
None 
Hearing loss 
Hypothyroid 
Lipodermato-
sclerosis 
ESRD 
Raynaud 
syndrome 
 
None None 
 
Atrial flutter 
Nonspecific intra- 
ventricular block 
Autism None 
Ventricular 
septal defect None None 
Abbreviations: AA= amino acid, M=male, F=female, N/A=not available, RAP M=mean right atrial pressure, PAP M=mean pulmonary arterial pressure, AOP M=mean aortic pressure, 
PVRi=pulmonary vascular resistance index, Art Sat=arterial oxygen saturation, PCWPm=mean pulmonary capillary wedge pressure, CI=cardiac index.  UK=United Kingdom cohort, CU=Columbia 
University cohort. 
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FIGURE LEGENDS 
 
Figure 1. Topologic analysis of the SUR1 protein encoded by ABCC8, and sequence alignment 
of ABCC8 across species. Panel A shows the topology of the SUR1 protein. The 17 
transmembrane segments are grouped into transmembrane domains (TMD): TMD0, TMD1, and 
TMD2. The two nucleotide-binding fold domains (NBF1 & 2) are indicated. Variants N72D, 
G111R, L135V, and E186D are located in TMD0; T229I and A240T are located in the 
cytoplasmic loop, L0; E791Q, D813N, and R958H are located in NBF1; R1314H and D1472N 
are located in NBF2. The position of each mutation is indicated by a red circle. Panel B shows 
the alignment of human ABCC8-encoding SUR1 protein with 14 different species, demonstrating 
conservation across species of each amino acid found mutated in this study.  
 
Figure 2. Electrophysiological consequence of SUR1 mutations on KATP (SUR1+Kir6.2) 
channel function. Whole-cell voltage clamp was used to measure expressed wildtype (WT) 
versus mutant KATP channel currents containing SUR1+Kir6.2 in COS7 cells. Panel A shows a 
wildtype SUR1-dependent KATP current trace. A voltage ramp from -120mV to +60mV over 1 
second was applied every 3 seconds, from a -80mV holding potential. For all sample current 
traces, the vertical scale is 100 pA/pF, and the horizontal scale is 20mV. Panel B shows SUR1-
dependent current traces of mutant KATP channels containing A240T, D813N, or D1472N SUR1 
as indicated. Panel C summarizes SUR1-dependent KATP current densities (pA/pF) for the eight 
SUR1 mutants evaluated and wildtype, measured at -40mV (indicated by the black arrow in 
Panel A); 8 to 30 cells were studied per condition. Data are shown as means; T bars indicate 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
18 
standard errors. Asterisks indicate P<0.05 for the comparison between wildtype SUR1 and each 
mutant, as calculated by a one-way ANOVA and post-hoc Tukey test. 
 
Figure 3. Functional impact of SUR1 mutations on macroscopic KATP (SUR1+Kir6.2) channel 
activity.  86Rb+ efflux was measured over time from COSm6 cells expressing KATP channels 
containing SUR1+Kir6.2. Panel A shows basal efflux for wildtype (WT, black curve) versus 
mutant (colored curves) SUR1-containing KATP channels, and GFP-alone (gray curve). Panel B 
displays the mean rate constants for KATP-dependent 86Rb+ efflux under basal conditions. Panel C 
shows efflux from cells exposed to solution containing oligomycin and 2-deoxy-D-glucose to 
induce metabolic inhibition of cells, thereby relieving KATP channels from intracellular inhibition 
by ATP. Wildtype versus mutant SUR1-containing KATP channels, and GFP-alone, are 
compared. The inset shows exponential fits to early time points which were used to derive the 
efflux rate constants (see Supplementary Table S3). Panel D shows the mean rate constants for 
KATP-dependent 86Rb+ efflux under metabolic inhibition conditions. For each condition, 7 to 10 
cell populations were studied. Data are shown as means; T bars indicate standard errors. 
Asterisks indicate P<0.05 for the comparison between wildtype SUR1 and each mutant, as 
calculated by a one-way ANOVA and post-hoc Tukey test.  
 
Figure 4. Pharmacological recovery of mutant KATP (SUR1+Kir6.2) channels. Diazoxide 
restores function of KATP channels (SUR1/Kir6.2) containing mutant SUR1. Panel A shows 
rubidium efflux in the presence of diazoxide 100µM for wildtype (WT) SUR1 (black curve), 
mutant SUR1-containing KATP channels (colored curves), and GFP-alone (gray curve). Panel B 
shows average efflux rates for wildtype and mutant KATP channels in basal (gray) versus 
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19 
diazoxide 100µM (black) conditions. For each condition, 7 to 9 cell populations were studied. 
Panel C depicts whole-cell drug time courses of wildtype and selected mutant KATP channel 
currents with varying degrees of pharmacological activation. Time course depicts before drug 
application (gray, control), during diazoxide 100µM application (black), and during co-
application of glibenclamide 10µM with diazoxide 100µM (red). The vertical scale is 25 pA/pF, 
and the horizontal scale is 1 minute. Arrows indicate the maximal steady-state current-d nsity 
(pA/pF) achieved during diazoxide 100µM application. Panel D summarizes current density 
(pA/pF at -40mV) for wildtype and each mutant SUR1-containing KATP channel, in control 
(gray) and diazoxide 100µM (black) conditions; 6 to 30 cells were studied per condition. Data 
are shown as means; T bars indicate standard errors. Asterisks denote P<0.05 for the comparison 
of basal and diazoxide (Panel B), or control and diazoxide (Panel D), calculated by the paired 
6WXGHQW¶Vt-test. 
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A
B
Human PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I I F ES P PDI DI L GLS RAM AVKR I H GGLDCA
Chimp PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I I F ES P PDI DI L GLS RAM AVKR I H GGLDCA
Hamster PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Mouse PGHNLR MPAGMA FPKLLI LLVEI N S KGTYW I KTAHR I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Rat PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Rabbit PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Pig PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Dolphin PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM XXXXXX GGLDCA
Cow PGHNLR MPAGMA FPKLLI LLVEI N S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Cat PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Dog PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGL= G=
Elephant PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAL AVKR I H GGLDCA
Chicken PGHNLR MPAGMA FPKLLI LAVEI N S KGTYW I KTAHK I TF ES S PDI DI L NLRRPM AVKR I H GGLDCA
Fugu PGHNLR MPAALA F PKLLL LAVEI N S KATYW I TS AHR = = = = = = PDI DI L = = = = = = S VKR I N = = = = CA
Zebrafish PGHNLR MPS CLA F PKLLI LAVEI N S KS TYW I TS AHR I TF EMP PDI DI L NLRRAM AVKR I K GGLDCA
D1472N
NBF1
R1314H	N72D
TMD0 L0 NBF2
R958H		G111R T229I A240T			E186D			L135V E791Q D813N
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